Cabozantinib Drug Encyclopedia

Cabozantinib (Cabozantinib) is a targeted therapy drug that belongs to the category of multi-target tyrosine kinase inhibitors. It is widely used in the treatment of many types of cancer, including advanced renal cell carcinoma, thyroid cancer, and hepatocellular carcinoma. Cabozantinib is also known medically as XL184.

As a targeted therapy, cabozantinib works mainly by inhibiting multiple key signaling pathways. It can inhibit the activity of multiple receptor tyrosine kinases (RTKs), including MET (hepatocyte growth factor receptor), VEGFR (vascular endothelial growth factor receptor) , RET (rearranged oncogene family receptor kinase), KIT (cytoplasmic tyrosine kinase) and AXL (axon-associated protein kinase), etc. These receptor tyrosine kinases play important roles in processes such as cancer cell proliferation, migration, and angiogenesis. By inhibiting the activity of these receptor tyrosine kinases, cabozantinib can effectively inhibit the growth and metastasis of tumor cells.

In addition to acting on the tumor cells themselves, cabozantinib can also inhibit the vascular endothelial growth factor (VEGF) signaling pathway, thereby inhibiting the formation of new blood vessels in the tumor, reducing the blood supply to the tumor, and thereby inhibiting tumor growth and metastasis.

The dosage form of cabozantinib is generally an oral preparation, and patients can take it as scheduled according to the doctor's prescription. Under normal circumstances, patients need to undergo regular physical examinations and related biochemical index tests while taking cabozantinib to evaluate the treatment effect and monitor the occurrence of adverse reactions. During the treatment process, patients should closely follow the doctor's instructions, take medications on time, and avoid missing doses or overdosing.

In general, cabozantinib, as a targeted therapy, has been proven to play an important role in the treatment of various types of cancer. However, during the use of cabozantinib, patients should closely follow the doctor's instructions, conduct regular monitoring, and promptly report any symptoms of discomfort to ensure the best treatment effect.